microdosing a glp 1 GLP-1 Microdosing: Slower, Smarter Path to Metabolic Health Why GLP-1 Microdosing? A Closer

These findings offer new hope for people with chronic kidney disease

The SURMOUNT-1 trial showed that tirzepatide, a dual GIP/GLP-1 receptor agonist, produced even greater weight loss (up to 20.9% at the highest dose) with proportional reductions in waist circumference

This method not only strengthens the evidence for the observed associations but also highlights GLP-1RAs as promising candidates for repurposing in the treatment of psychiatric and neurodevelopmental conditions

The JAHA meta-analysis found that DVT risk was significantly higher in studies with treatment duration exceeding 1.5 years (OR 2.32 vs 1.64 overall)

How Does Empagliflozin Reduce Cardiovascular Mortality

Finally, the pathway analysis was performed using ShinyGO v0.80 83 and Reactome 84 to investigate the enriched pathways associated with the significant proteins identified by the Random Forest method and Volcano plots